Clinical Trial

FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products

TORONTO, ON / ACCESSWIRE / April 17, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

2 months ago

IGM Biosciences Announces Refocusing of Sanofi Collaboration

Agreement focuses on immunology/inflammation, aligning with Sanofi’s ongoing commitment to advancing therapies for patients across multiple inflammatory diseasesMOUNTAIN VIEW, Calif.,…

2 months ago

Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed…

2 months ago

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for…

2 months ago

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

The new oncology committee will include: Jason Hafron, MD, DDS, PhD, MPH; and Pradeep Tyagi, PhD, MBAPITTSBURGH, Pa., April 17,…

2 months ago

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

New patent-protected, central recruitment leverages the Science 37 Metasite™ to accelerate enrollment and dramatically reduce site burdenRESEARCH TRIANGLE PARK, N.C.,…

2 months ago

Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds

MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing…

2 months ago

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company…

2 months ago

Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)

Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaignR327 manufactured under GMP…

2 months ago

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that…

2 months ago